Meridian Holdings Inc./NV — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Meridian Holdings Inc./NV filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $182.86M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $151.12M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $92.99M | Mar 24, 2025 |
| FY2023 | Oct 31, 2023 | $44.17M | Jan 17, 2024 |
| FY2023 | Oct 31, 2022 | $36.03M | Jan 17, 2024 |
| FY2022 | Oct 31, 2021 | $9.33M | Jan 30, 2023 |
| FY2022 | Jul 31, 2021 | $11.29M | Jan 30, 2023 |
| FY2022 | Jan 31, 2021 | $5.22M | Jan 30, 2023 |
| FY2022 | Jan 31, 2020 | $1.76M | Jan 30, 2023 |
| FY2021 | Jul 31, 2019 | $452.8K | Apr 30, 2021 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Jul 31, 2015 | $0 | Nov 13, 2015 |
| FY2015 | Jul 31, 2014 | $0 | Nov 13, 2015 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $103.46M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $88.57M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $68.24M | Mar 24, 2025 |
| FY2023 | Oct 31, 2023 | $9.87M | Jan 17, 2024 |
| FY2023 | Oct 31, 2022 | $9.16M | Jan 17, 2024 |
| FY2022 | Oct 31, 2021 | $3.28M | Jan 30, 2023 |
| FY2022 | Jan 31, 2021 | $3.22M | Jan 30, 2023 |
| FY2022 | Jan 31, 2020 | $1.70M | Jan 30, 2023 |
| FY2021 | Jul 31, 2019 | $2.86M | Apr 30, 2021 |
| FY2021 | Jul 31, 2018 | $843.8K | Apr 30, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($91.98M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($1.41M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $13.70M | Mar 24, 2025 |
| FY2023 | Oct 31, 2023 | ($1.17M) | Jan 17, 2024 |
| FY2023 | Oct 31, 2022 | $44.0K | Jan 17, 2024 |
| FY2022 | Oct 31, 2021 | $648.1K | Jan 30, 2023 |
| FY2022 | Jan 31, 2021 | $398.1K | Jan 30, 2023 |
| FY2022 | Jan 31, 2020 | $966.8K | Jan 30, 2023 |
| FY2021 | Jul 31, 2019 | $1.77M | Apr 30, 2021 |
| FY2021 | Jul 31, 2018 | ($1.32M) | Apr 30, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($96.17M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $2.74M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $13.76M | Mar 24, 2025 |
| FY2023 | Oct 31, 2023 | ($526.2K) | Jan 17, 2024 |
| FY2023 | Oct 31, 2022 | $192.5K | Jan 17, 2024 |
| FY2022 | Oct 31, 2021 | $750.9K | Jan 30, 2023 |
| FY2022 | Jan 31, 2021 | $399.3K | Jan 30, 2023 |
| FY2022 | Jan 31, 2020 | $974.3K | Jan 30, 2023 |
| FY2021 | Jul 31, 2019 | $1.81M | Apr 30, 2021 |
| FY2021 | Jul 31, 2018 | ($990.9K) | Apr 30, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.10M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $6.07M | Mar 31, 2026 |
| FY2022 | Oct 31, 2022 | $23.1K | Jan 30, 2023 |
| FY2022 | Oct 31, 2021 | $149.7K | Jan 30, 2023 |
| FY2022 | Jan 31, 2021 | $47.6K | Jan 30, 2023 |
| FY2022 | Jan 31, 2020 | $0 | Jan 30, 2023 |
| FY2021 | Jul 31, 2019 | $0 | Apr 30, 2021 |
| FY2021 | Jul 31, 2018 | $0 | Apr 30, 2021 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $199.63M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $85.83M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $54.48M | Mar 24, 2025 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $25.36M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $23.92M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $23.69M | Mar 24, 2025 |
| FY2023 | Oct 31, 2023 | $2.21M | Jan 17, 2024 |
| FY2023 | Oct 31, 2022 | $2.77M | Jan 17, 2024 |
| FY2022 | Oct 31, 2021 | $1.27M | Jan 30, 2023 |
| FY2022 | Jan 31, 2021 | $1.88M | Jan 30, 2023 |
| FY2022 | Jan 31, 2020 | $986.7K | Jan 30, 2023 |
| FY2021 | Jul 31, 2019 | $1.45M | Apr 30, 2021 |
| FY2021 | Jul 31, 2018 | $302.7K | Apr 30, 2021 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.18M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $7.16M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $5.74M | Mar 24, 2025 |
| FY2023 | Oct 31, 2023 | $12.5K | Jan 17, 2024 |
| FY2023 | Oct 31, 2022 | $36.8K | Jan 17, 2024 |
| FY2015 | Jul 31, 2014 | ($2.0K) | Nov 12, 2014 |
| FY2013 | Jul 31, 2013 | ($2.0K) | Apr 8, 2014 |
| FY2013 | Jul 31, 2012 | ($2.0K) | Apr 8, 2014 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $118.08M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $213.72M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $79.85M | Mar 24, 2025 |
| FY2023 | Oct 31, 2023 | $35.58M | Jan 17, 2024 |
| FY2023 | Oct 31, 2022 | $32.57M | Jan 17, 2024 |
| FY2022 | Oct 31, 2021 | $20.46M | Jan 30, 2023 |
| FY2021 | Jan 31, 2021 | $13.81M | Apr 30, 2021 |
| FY2021 | Jan 31, 2020 | $3.71M | Apr 30, 2021 |
| FY2019 | Jul 31, 2019 | $3.01M | Oct 23, 2019 |
| FY2019 | Jul 31, 2018 | $819.9K | Oct 23, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $69.74M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $104.77M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $19.87M | Mar 24, 2025 |
| FY2023 | Oct 31, 2023 | $4.48M | Jan 17, 2024 |
| FY2023 | Oct 31, 2022 | $2.77M | Jan 17, 2024 |
| FY2022 | Oct 31, 2021 | $1.53M | Jan 30, 2023 |
| FY2021 | Jan 31, 2021 | $552.6K | Apr 30, 2021 |
| FY2021 | Jan 31, 2020 | $1.23M | Apr 30, 2021 |
| FY2019 | Jul 31, 2019 | $1.97M | Oct 23, 2019 |
| FY2019 | Jul 31, 2018 | $2.16M | Oct 23, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $46.55M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $105.07M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $59.03M | Mar 24, 2025 |
| FY2023 | Oct 31, 2023 | $31.10M | Jan 17, 2024 |
| FY2023 | Oct 31, 2022 | $26.80M | Jan 17, 2024 |
| FY2022 | Oct 31, 2021 | $18.93M | Jan 30, 2023 |
| FY2022 | Jan 31, 2021 | $13.26M | Jan 30, 2023 |
| FY2022 | Jan 31, 2020 | $2.47M | Jan 30, 2023 |
| FY2022 | Jul 31, 2019 | $1.03M | Jan 30, 2023 |
| FY2021 | Jul 31, 2018 | ($1.34M) | Apr 30, 2021 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.45M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $71.25M | Mar 31, 2026 |
| FY2023 | Oct 31, 2023 | $10.38M | Jan 17, 2024 |
| FY2023 | Oct 31, 2022 | $10.45M | Jan 17, 2024 |
| FY2022 | Oct 31, 2021 | $0 | Jan 30, 2023 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($33.07M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $57.05M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $59.30M | Mar 24, 2025 |
| FY2023 | Oct 31, 2023 | ($25.85M) | Jan 17, 2024 |
| FY2023 | Oct 31, 2022 | ($24.67M) | Jan 17, 2024 |
| FY2022 | Oct 31, 2021 | ($24.42M) | Jan 30, 2023 |
| FY2021 | Jan 31, 2021 | ($25.07M) | Apr 30, 2021 |
| FY2021 | Jan 31, 2020 | ($25.47M) | Apr 30, 2021 |
| FY2019 | Jul 31, 2019 | ($26.44M) | Oct 23, 2019 |
| FY2019 | Jul 31, 2018 | ($28.21M) | Oct 23, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Oct 31, 2022 | $14.95M | Jan 30, 2023 |
| FY2022 | Oct 31, 2021 | $16.80M | Jan 30, 2023 |
| FY2021 | Jan 31, 2021 | $11.71M | Apr 30, 2021 |
| FY2021 | Jan 31, 2020 | $1.86M | Apr 30, 2021 |
| FY2021 | Jul 31, 2019 | $1.73M | Apr 30, 2021 |
| FY2021 | Jul 31, 2018 | $446.6K | Apr 30, 2021 |
| FY2021 | Jul 31, 2017 | $25.2K | Apr 30, 2021 |
| FY2018 | Jul 31, 2016 | $2.3K | Oct 29, 2018 |
| FY2016 | Jul 31, 2015 | $0 | Nov 15, 2016 |
| FY2016 | Jul 31, 2014 | $636 | Nov 15, 2016 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (7) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 24, 2025 |
| FY2023 | Oct 31, 2023 | 0 | Jan 17, 2024 |
| FY2023 | Oct 31, 2022 | 0 | Jan 17, 2024 |
| FY2022 | Oct 31, 2021 | 0 | Jan 30, 2023 |
| FY2022 | Jan 31, 2021 | 0 | Jan 30, 2023 |
| FY2022 | Jan 31, 2020 | 0 | Jan 30, 2023 |
| FY2021 | Jul 31, 2019 | 0 | Apr 30, 2021 |
| FY2021 | Jul 31, 2018 | 0 | Apr 30, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (7) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 24, 2025 |
| FY2023 | Oct 31, 2023 | 0 | Jan 17, 2024 |
| FY2023 | Oct 31, 2022 | 0 | Jan 17, 2024 |
| FY2022 | Oct 31, 2021 | 0 | Jan 30, 2023 |
| FY2022 | Jan 31, 2021 | 0 | Jan 30, 2023 |
| FY2022 | Jan 31, 2020 | 0 | Jan 30, 2023 |
| FY2021 | Jul 31, 2019 | 0 | Apr 30, 2021 |
| FY2021 | Jul 31, 2018 | 0 | Apr 30, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 12.64M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 10.77M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 83.48M | Mar 24, 2025 |
| FY2023 | Oct 31, 2023 | 36.16M | Jan 17, 2024 |
| FY2023 | Oct 31, 2022 | 28.18M | Jan 17, 2024 |
| FY2022 | Oct 31, 2021 | 27.23M | Jan 30, 2023 |
| FY2021 | Jan 31, 2021 | 22.74M | Apr 30, 2021 |
| FY2021 | Jan 31, 2020 | 18.97M | Apr 30, 2021 |
| FY2019 | Jul 31, 2019 | 2.85B | Oct 23, 2019 |
| FY2019 | Jul 31, 2018 | 2.62B | Oct 23, 2019 |